Table 1 Selected publications between 2005 and 2019 in Web of Science database according to the following search terms: (mesenchymal stem cells) AND (fetal bovine serum OR fetal bovine calf) AND (human platelet lysate), its acronyms and complete bibliography checking

(Kong et al. 2019)

hUMC-MSCs

10% FBS, 10% hPL, 10% HS

I

N.M.

N.M

1

3–4 days

2

2

1

(Barro et al. 2019)

BM-MSCs

FBS, hPL, i-hPL

Aph

SD + UV, FT

0.22/0.1 µm

3

3–4 days

1

1

1

(Lensch et al. 2018)

ASC-MSCs

FBS 10%, xeno free media

I

N.M.

N.M

1

3–4 days

1

1

1

(Haack-Sørensen et al. 2018)

ASC-MSCs

10% FBS, 5% hPL

I

N.M.

N.M

1

N.M.

3

1

1

(Dessels et al. 2019)

ASC-MSCs

FBS 10%, 10%, 5% hPL

BC

FT

0.22 µm

0

3–4 days

1

1

1

(Becherucci et al. 2018)

BM-MSCs

FBS 10%, hPL 5%

BC

FT

0.45/0.22 µm

1

3–4 days

1

1

1

(Chen et al. 2019)

hUMC-MSCs

10% FBS, 6.55%(FTPL), 6.50%(GBPL), 7.50% (SDPL), 6.72% GBHPL

Aph

SD + Ca, FT

0.22 µm

A−/B+

3–4 days

1

1

1

(Ren et al. 2018)

BM-MSCs

20% FBS, 10% HPGF-C18

Aph

SD

0.2 µm

0

3–4 days

2

2

1

(Kandoi et al. 2018)

hUMC-MSCs

20% FBS, 10%, 5% hPL

N.M.

FT

N.M

1

3–4 days

2

1

1

(Phetfong et al. 2017)

ASC-MSCs

10% FBS, 10% hPL, 10% hPL + hPlasma

N.M.

FT

0.2 µm

B

1 day

1

1

1

(Søndergaard et al. 2017)

ASC-MSCs

10% FBS, 5% hPL

I

N.M.

N.M

0

3–4 days

1

1

1

(Mangum et al. 2017)

ASC-MSCs

FBS 10%, hPL 10%

I

N.M.

N.M

A−/B+

N.M.

3

1

2

(Bernardi et al. 2017)

BM-MSCs

10% FBS, 10%, 7.5%, 5% hPL, 10% 7.5% 5% PR-SRGF

Aph

Ca, FT

70 µm

1

3–4 days

3

2

1

(Pierce et al. 2017)

BM-MSCs

10% FBS, 10% PL-S, 10% PL-P

PRP

Ca

N.M

0

3–4 days

3

1

2

(Fernandez-Rebollo et al. 2017)

BM-MSCs

10%FBS, 10% hPL

Aph

FT

0.2 µm

1

N.M.

1

1

1

(Matthyssen et al. 2017)

hC-MSCs

FBS, hPL, hS 2.5%, 5%, 10%

I

N.M.

N.M

1

N.M.

1

1

1

(Viau et al. 2017)

BM-MSCs

2-15% FBS + bFGF, hPL, PR-hPL

BC

UV, FT

N.M

1

3–4 days

3

1

1

(Riis et al. 2016)

ASC-MSCs

10% FBS, 10%, 5% hPL

I

N.M.

N.M

0

3–4 days

4

1

2

(Escobar and Chaparro, 2016)

ASC-MSCs

FBS 10%, hPL 5%

BC

FT

0.22 µm

A−/B+

3–4 days

2

1

1

(Heathman et al. 2016)

BM-MSCs

10% FBS, 10% PL

I

N.M.

N.M

1

3–4 days

3

1

1

(Mohammadi et al. 2016)

hUMC-MSCs

10% FBS, 2%, 5%, 7%, 10% PL

PRP

N.M.

N.M

1

3–4 days

1

1

2

(Shirzad et al. 2017)

hUMC-MSCs

10% FBS, 10%, 5% UCB-PL, PB-PL

PRP

FT

N.M

3

3–4 days

2

1

2

(Suri et al. 2016)

hC-MSCs

10% FBS, 10% PHPL, 10% hPL

Aph

FT

N.M

0

N.M.

2

2

1

(Juhl et al. 2016)

ASC-MSCs and BMSCs

10% FBS, 5% PLTMax, 5% hPLS, 5% hPLSP

I

N.M.

N.M

1

3–4 days

1

1

1

(Muraglia et al. 2015)

BMSCs, ASCs, UC-MSCs, T-lymph

10% FCS, 5% PPP, hPL

PRP

FT

N.M

1

3–4 days

3

1

1

(Wagner et al. 2015)

ASC-MSCs and hF

10% FBS, 5% hPL

Aph

FT

0.2 µm

1

N.M.

3

1

3

(Riordan et al. 2015)

hUMC-MSCs

10% FBS, 5%, 7.5%, 10% XcytePLUS-hPL

N.M.

N.M.

N.M

1

N.M.

2

1

1

(Castiglia et al. 2014)

BM-MSCs

10% FBS, 10% hPL, 10% iHPL

BC

UV

0.2 µm

1

3–4 days

1

2

1

Trojahn Kølle et al. 2013)

ASC-MSCs

10% FBS, 10% hPL

PRP

FT

0.2 µm

1

3–4 days

1

1

1

(Witzeneder et al. 2013)

ASC-MSCs and hF

10% FBS, 5% hPLp, 5% hPLn, 10% huS

BC

FT

N.M

1

3–4 days

2

1

3

(Kinzebach and Bieback, 2013)

ASC-MSCs and BMSC

10%, 7.5%, 5%, 2.5% FBS, pHPL, tPRP

BC

Thr, FT

0.45 µm

A−/B+

N.M.

3

1

3

(Mojica-Henshaw et al. 2013)

MSCs

10%FBS, 10% hPLp, 10% hPLs

PRP

Ca, FT

0.22 µm

A

3–4 days

3

1

1

(Bernardi et al. 2013)

BM-MSCs

10% FBS, 10% PLT-FT-Ly, 7.5%, 5%, 2.5% PLT

PRP

Son, FT

70 µm

1

3–4 days

3

1

1

(Shanskii et al. 2013)

ASC-MSCs

10/0, 7.5/2.5, 5/5, 2.5/7.5, 0/10% FBS, hPL

N.M.

FT

N.M

0

N.M.

3

1

3

(Griffiths et al. 2013)

BM-MSCs

16% FBS, 2%, 5%, 10% hPL

PRP

FT

N.M

1

N.M.

1

1

1

(Ben Azouna et al. 2012)

BM-MSCs

10%FBS, 10% FBS + 5% hPL, 10% hPL, 5% hPL

Aph

FT

N.M

AB−

3–4 days

1

1

1

(Gottipamula et al. 2012)

BM-MSCs

10% FBS, 10% hPL

N.M.

FT

N.M

3

N.M.

1

1

1

(Fekete et al. 2012)

BM-MSCs

20% FBS, 10% hPL

BC

UV, FT

0.45/0.22 µm

1

3–4 days

3

2

1

(Schallmoser and Strunk, 2013)

hUMC-MSCs

10% FBS, 2.5, 5, 10% pHPL

BC, Aph

FT

0.22 µm

0

N.M.

3

1

3

(Naaijkens et al. 2012)

ASC-MSCs

10% FBS, 5% hPL

BC

FT

N.M

0

3–4 days

1

1

1

(Shih et al. 2011)

ASC-MSCs

10% FBS, 10% hPL

N.M.

SD

0.2 µm

C

3–4 days

2

1

1

(Crespo-Diaz et al. 2011)

ASC-MSCs and BMSCs

FBS 10%, hPL 5%

N.M.

FT

70 µm

1

N.M.

3

1

1

(Govindasamy et al. 2011)

DPSCs

10% FBS, 10% hPL

PRP

FT

0.40 µm

1

3–4 days

1

1

1

(Shichinohe et al. 2011)

BM-MSCs

10% FBS, 5% hPL

PRP

FT

N.M

N

3–4 days

2

3

1

(Xia et al. 2011)

BM-MSCs

10% FBS, 7.5% hPL

Aph

FT

0.22 µm

A−/B+

N.M.

1

2

1

(Cholewa et al. 2011)

ASC-MSCs

10% FBS, 10% hPL

N.M.

FT

N.M

1

3–4 days

1

1

1

(Abdelrazik et al. 2011)

BM-MSCs

10% FBS, 10% hPL

Aph

FT

N.M

0

3–4 days

3

1

1

(Horn et al. 2010)

BM-MSCs

10%FBS, 10% hPL

BC, Aph

FT

0.2 µm

1

3–4 days

2

2

1

(Blande et al. 2009)

ASC-MSCs

10% FBS, 2.5%, 10% hPL

N.M.

FT

0.22 µm

1

1 day

1

1

2

(Bieback et al. 2009)

BM-MSCs

10% FBS, 10% HS, 10% tPRP, 10% pHPL

PRP

Thr, FT

0.2 µm

1

3–4 days

1

1

1

(Prins et al. 2009)

BM-MSCs

10% FBS, 5% hPL

N.M.

FT

N.M

1

3–4 days

1

1

1

(Zaky et al. 2008)

BM-MSCs

10% FBS, 5% hPL

PRP

FT

N.M

1

3–4 days

1

1

3

(Schallmoser et al. 2007)

BM-MSCs

10% FBS, hPL 10%

PRP

FT

0.22 µm

1

3–4 days

1

1

1

(Capelli et al. 2007)

BM-MSCs

10% FBS, 5% hPL

PRP

FT

N.M

1

3–4 days

2

1

1

(Reinisch et al. 2007)

hUMC-MSCs

10% FBS, 10% hPL

PRP

FT

0.22 µm

1

3–4 days

2

1

1

(Doucet et al. 2005)

BM-MSCs

10% FBS, 5% hPL

Aph

FT

N.M

A

3–4 days

3

1

1